Загрузка...
Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States
INTRODUCTION: Eculizumab is a licensed treatment for several rare, complement-mediated diseases. Eculizumab use is associated with an approximately 2,000-fold increased meningococcal disease risk. In the United States, meningococcal vaccines are recommended for eculizumab recipients but there are no...
Сохранить в:
| Опубликовано в: : | PLoS One |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Public Library of Science
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7660549/ https://ncbi.nlm.nih.gov/pubmed/33180804 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0241989 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|